Replies to post #162062 on Biotech Values

[DewDiligence]

SNY also killed the Iniparib (PARP-inh) program and will take a $285M (non-cash) writeoff for the failure:

http://www.bloomberg.com/news/2013-06-03/sanofi-ends-iniparib-research-plans-285-million-charge.html

[DewDiligence]

Quiz (low difficulty): Why did SNY take a writeoff for the failure of Iniparib (#msg-88593358) but not for the failure of Otamixaban (#msg-88592744)?

[turtlepower]

Like PTLA’s Betrixaban (which is still in development but shouldn’t be, IMO)

Any particular reason for saying that? Seemed like an interesting pipeline but curious why you think the lead drug could be a dud. Thanks.